Royalty Pharma plc

Royalty Pharma plc (RPRX) priced its initial public offering on Jun 17, 2020 at $28.00 per share, within its $25.00–$28.00 range, raising $2.18B, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $16.67B. BofA Securities was lead-left underwriter, joined by Goldman Sachs, Citigroup and UBS. Davis Polk and Akin advised the company and Goodwin Procter advised the underwriters.

Royalty Pharma plc buys biopharmaceutical royalties and funds innovation across the biopharmaceutical industry. Founded in 1996, it works with innovators from academic institutions, research hospitals and not-for-profits.

Status

IPO

Ticker

RPRX

Exchange

Nasdaq Global Select

Priced

Jun 17, 2020

IPO price

$28.00

Price range

$25.00–$28.00

Raised

$2.18B

Market cap at IPO price

$16.67B

First filed

May 22, 2020

Underwriters

BofA Securities, Goldman Sachs, Citigroup and UBS

Company counsel

Davis Polk and Akin

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

NY

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.